Neuronetics, Inc. (STIM) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates a positive outlook with a 12% revenue increase and improved gross margin. Operating expenses grew modestly, while net loss decreased, showing operational efficiency. The lack of strategic initiatives or return discussions in the call is balanced by strong financial performance and improved margins, suggesting a positive sentiment.
Key Financial Performance
Revenue $18.5 million, a 12% increase year-over-year, driven by strong sales performance and increased adoption of the company's therapy systems.
Gross Margin 74%, an improvement from 70% year-over-year, attributed to better cost management and operational efficiencies.
Operating Expenses $15 million, a 5% increase year-over-year, primarily due to higher investments in sales and marketing initiatives.
Net Loss $2.5 million, a reduction from $3.2 million year-over-year, reflecting improved operational performance and revenue growth.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company acknowledges that actual results can differ materially from forward-looking statements due to risks and uncertainties associated with the business.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Adam Maeder
CEO President
Canaccord Genuity
Co Research
Corp Research
Director Klausner
Division Adam
Division EDT
Division Stauder
EDT day
Financial Results
Genuity Corp
Instructions today
Klausner Westwicke
LLC Plovanic
Maeder Piper
Neuronetics Financial
Partners LLC
Piper Sandler
Plovanic Canaccord
President Director
Research Division
Results Instructions
Sandler Co
Stauder Citizens
Westwicke Partners
conference speaker
day Neuronetics
speaker today
STIM Transcript
Neuronetics, Inc. (STIM) Q1 2026 Earnings Call Transcript
Positive5-5
The earnings call summary indicates a positive outlook with a 12% revenue increase and improved gross margin. Operating expenses grew modestly, while net loss decreased, showing operational efficiency. The lack of strategic initiatives or return discussions in the call is balanced by strong financial performance and improved margins, suggesting a positive sentiment.
Neuronetics, Inc. (STIM) Q4 2025 Earnings Call Transcript
Unknown3-17
The earnings call reflects mixed signals: improved financial performance, but lower gross margins and ongoing CID investigation. Positive aspects include increased treatment and clinic revenues, reduced net loss, and optimistic guidance. However, the Q&A session highlighted risks, such as the CID investigation and vague details on COMP360 profitability and exclusivity. The lack of clear guidance and lower Q1 expectations due to seasonality and weather also contribute to a neutral outlook. The mixed sentiment is balanced by operational improvements and growth in SPRAVATO treatments.
Neuronetics, Inc. (STIM) Q3 2025 Earnings Call Transcript
Unknown11-4
Despite record revenue growth and improved cash flow, the stock may not experience significant movement due to lowered gross margin guidance and unchanged operational efficiencies. Although Q4 guidance is optimistic, the market may remain cautious due to uncertainties in purchasing patterns and margin pressures. The Q&A session revealed confidence in growth segments but lacked detailed operational efficiency metrics, contributing to a neutral sentiment.
Neuronetics, Inc. (STIM) Q2 2025 Earnings Call Transcript
Positive8-5
The earnings call indicates several positive developments: improved cash management, operational efficiencies, and strong adolescent patient growth. Despite a consistent net loss, the per-share loss improved, and EBITDA showed progress. The Q&A reveals strategic shifts and revenue cycle improvements, with optimistic guidance for Q4. However, some concerns remain, such as slower traditional STIM business and lack of specific targets. Overall, the positive aspects, including the potential for cash flow positivity and revenue growth, suggest a positive stock price movement.
STIM Slides
STIM Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
